Azole-echinocandin Combination Therapy for Invasive Aspergillosis (IA-DUET)
Azole-echinocandin Combination Therapy for Invasive Aspergillosis A Randomized Pragmatic Superiority Trial
Sponsor: Erasmus Medical Center
Terminated
futility
This PHASE3 trial investigates Invasive Aspergillosis and is currently terminated or withdrawn. Erasmus Medical Center leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Nov 2021 — Jun 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
May 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Erasmus Medical Center
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- ZonMw: The Netherlands Organisation for Health Research and Development
For direct contact, visit the study record on ClinicalTrials.gov .